Strategies to Facilitate Access to High-Cost Anti-Cancer Drugs: A Systematic Review of the Literature

2020 ◽  
Author(s):  
Chanthawat Patikorn ◽  
Rungpetch Sakulbumrungsil ◽  
Dennis Ross-Degnan ◽  
Suthira Taychakhoonavudh ◽  
Puree Anantachoti
Cells ◽  
2019 ◽  
Vol 8 (5) ◽  
pp. 418 ◽  
Author(s):  
Yoshikatsu Koga ◽  
Atsushi Ochiai

Patient-derived xenograft (PDX) models are used as powerful tools for understanding cancer biology in PDX clinical trials and co-clinical trials. In this systematic review, we focus on PDX clinical trials or co-clinical trials for drug development in solid tumors and summarize the utility of PDX models in the development of anti-cancer drugs, as well as the challenges involved in this approach, following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Recently, the assessment of drug efficacy by PDX clinical and co-clinical trials has become an important method. PDX clinical trials can be used for the development of anti-cancer drugs before clinical trials, with their efficacy assessed by the modified response evaluation criteria in solid tumors (mRECIST). A few dozen cases of PDX models have completed enrollment, and the efficacy of the drugs is assessed by 1 × 1 × 1 or 3 × 1 × 1 approaches in the PDX clinical trials. Furthermore, co-clinical trials can be used for personalized care or precision medicine with the evaluation of a new drug or a novel combination. Several PDX models from patients in clinical trials have been used to assess the efficacy of individual drugs or drug combinations in co-clinical trials.


Oncotarget ◽  
2015 ◽  
Vol 6 (37) ◽  
pp. 39538-39549 ◽  
Author(s):  
Alberto Ocana ◽  
Josee-Lyne Ethier ◽  
Laura Díez-González ◽  
Verónica Corrales-Sánchez ◽  
Amirrtha Srikanthan ◽  
...  

2020 ◽  
Vol 152 ◽  
pp. 102991 ◽  
Author(s):  
Giuseppe Di Lorenzo ◽  
Rossella Di Trolio ◽  
Zisis Kozlakidis ◽  
Giuseppina Busto ◽  
Concetta Ingenito ◽  
...  

2014 ◽  
Vol 32 (7) ◽  
pp. 651-680 ◽  
Author(s):  
Fabrice Smieliauskas ◽  
Chun-Ru Chien ◽  
Chan Shen ◽  
Daniel M. Geynisman ◽  
Ya-Chen Tina Shih

2020 ◽  
Vol 5 (1) ◽  
pp. 326-338 ◽  
Author(s):  
Kristen Weidner ◽  
Joneen Lowman

Purpose We conducted a systematic review of the literature regarding adult telepractice services (screening, assessment, and treatment) from approximately 2014 to 2019. Method Thirty-one relevant studies were identified from a literature search, assessed for quality, and reported. Results Included studies illustrated feasibility, efficacy, diagnostic accuracy, and noninferiority of various speech-language pathology services across adult populations, including chronic aphasia, Parkinson's disease, dysphagia, and primary progressive aphasia. Technical aspects of the equipment and software used to deliver services were discussed. Some general themes were noted as areas for future research. Conclusion Overall, results of the review continue to support the use of telepractice as an appropriate service delivery model in speech-language pathology for adults. Strong research designs, including experimental control, across multiple well-described settings are still needed to definitively determine effectiveness of telepractice services.


VASA ◽  
2020 ◽  
pp. 1-6 ◽  
Author(s):  
Marina Di Pilla ◽  
Stefano Barco ◽  
Clara Sacco ◽  
Giovanni Barosi ◽  
Corrado Lodigiani

Summary: A 49-year-old man was diagnosed with pre-fibrotic myelofibrosis after acute left lower-limb ischemia requiring amputation and portal vein thrombosis. After surgery he developed heparin-induced thrombocytopenia (HIT) with venous thromboembolism, successfully treated with argatroban followed by dabigatran. Our systematic review of the literature supports the use of dabigatran for suspected HIT.


2017 ◽  
Vol 22 (3) ◽  
pp. 159-166 ◽  
Author(s):  
Bastianina Contena ◽  
Stefano Taddei

Abstract. Borderline Intellectual Functioning (BIF) refers to a global IQ ranging from 71 to 84, and it represents a condition of clinical attention for its association with other disorders and its influence on the outcomes of treatments and, in general, quality of life and adaptation. Furthermore, its definition has changed over time causing a relevant clinical impact. For this reason, a systematic review of the literature on this topic can promote an understanding of what has been studied, and can differentiate what is currently attributable to BIF from that which cannot be associated with this kind of intellectual functioning. Using Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) criteria, we have conducted a review of the literature about BIF. The results suggest that this condition is still associated with mental retardation, and only a few studies have focused specifically on this condition.


Author(s):  
L. Kristjanson ◽  
E. Lobb ◽  
S. Aoun ◽  
L. Monterosso

Sign in / Sign up

Export Citation Format

Share Document